Molecular Templates (NASDAQ:MTEM) announced its quarterly earnings data on Monday. The biotechnology company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.02), Fidelity Earnings reports. Molecular Templates had a negative return on equity of 9.14% and a negative net margin of 42.15%. The business had revenue of $5.45 million for the quarter, compared to the consensus estimate of $6.00 million.
Shares of MTEM stock opened at $4.97 on Wednesday. The firm has a market capitalization of $190.46 million, a PE ratio of -4.87 and a beta of 2.77. The company has a 50-day moving average of $7.03. The company has a current ratio of 3.24, a quick ratio of 3.24 and a debt-to-equity ratio of 0.14. Molecular Templates has a 1-year low of $3.19 and a 1-year high of $8.77.
Several analysts recently weighed in on MTEM shares. UBS Group started coverage on Molecular Templates in a research report on Monday, April 29th. They set a “buy” rating and a $12.00 price objective for the company. TheStreet downgraded Molecular Templates from a “c-” rating to a “d” rating in a research report on Monday, August 5th. Cowen restated a “buy” rating on shares of Molecular Templates in a research report on Tuesday. ValuEngine downgraded Molecular Templates from a “hold” rating to a “sell” rating in a research report on Thursday, August 1st. Finally, BidaskClub downgraded Molecular Templates from a “hold” rating to a “sell” rating in a research report on Friday, July 26th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $13.58.
Molecular Templates, Inc, a clinical stage oncology company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other diseases. The company primarily develops a pipeline of engineered toxin bodies. Its lead drug candidate is MT-3724 that is in a Phase II clinical trial for the treatment of relapsed/refractory diffuse large B-cell lymphoma; and Phase II clinical trial for treating non-Hodgkin's lymphoma.
Receive News & Ratings for Molecular Templates Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Templates and related companies with MarketBeat.com's FREE daily email newsletter.